1. Marek J. Hypofyzární adenomy dnes a zítra. Postgraduál Med 2008; 10 (Suppl 1): 39–41.
2. Melmed S, Colao A, Barkan A et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94: 1509–1517.
3. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 2005; 152: 379–387.
4. Petrossians P, Borges‑Martins L, Espinoza C et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005; 152: 61–66.
5. Karavitaki N, Turner HE, Adams CB. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 2008; 68: 970–975.
6. Vladyka V, Liščák R, Novotný J Jr et al. Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas. Neurosurgery 2003; 52: 309–317.
7. Ježková J, Marek J, Hána V et al. Gamma knife radiosurgery for acromegaly – long‑term experience. Clin Endocrinol 2006; 64: 588–595.
8. Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83: 374–378.
9. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93: 2957–2968.
10. Ashwell SG, Bevan JS, Edwards OM. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004; 150: 473–480.
11. Mercado M, Borges F, Bouterfa H et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long‑acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007; 66: 859–868.
12. Cozzi R, Attanasio R, Lodrini S et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004; 61: 209–215.
13. Selvarajah D, Webster J, Ross R et al. Effectiveness of adding dopamine agonist therapy to long‑acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005; 152: 569–574.
14. Giustina A, Bonadonna S, Bugari G et al. High‑dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009; 161: 331–338.
15. Freda PU, Katznelson L, van der Lely AJ et al. Long‑acting somatostatin analog therapy of acromegaly: a meta‑analysis. J Clin Endocrinol Metab 2005; 90: 4465–4473.
16. Cozzi R, Montini M, Attanasio R et al. Primary treatment of acromegaly with octreotide LAR: a long‑term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91: 1397–1403.
17. Kopchick JJ, Parkinson C, Stevens EC et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002; 23: 623–646.
18. van der Lely AJ, Hutson RK, Trainer PJ et al. Long‑term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754–1759.
19. Brue T. Acrostudy: Status update on 469 patients. Horm Res 2009; 71 (Suppl 1): 34–38.
20. Colao A, Arnaldi G, Beck‑Peccoz P et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 2007; 30: 693–699.
21. Buchfelder M, Weigel D, Droste M et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re‑evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 2009; 161: 27–35.
22. van der Lely AJ, Kopchick JJ. Growth hormone receptor antagonists. Neuroendocrinology 2006; 83: 264–268.
23. Parkinson C, Burman P, Messig M et al. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007; 92: 190–195.
24. Nomikos P. Modulation of radiation response by drugs in pituitary adenomas – latest information. Abstracts of the 15th International Meeting of the Leksell Gamma Knife Society. May 16–20. 2010, Athens, p. 82.
25. Ono M, Miki N, Kawamata T et al. Prospective study of high‑dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008; 93: 4721–4727.
26. Ježková J, Hána V, Kršek M et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf) 2009; 70: 732–741.
27. Ježková J, Marek J. Diagnosis and treatment of prolactinomas. Expert Rev Endocrinol Metab 2009; 4: 135–142.
28. Molitch ME. Pregnancy and the hyperprolactinemic women. N Engl J Med 1985; 312: 1364–1370.
29. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65: 823–827.
30. Colao A, Abs R, Bárcena DG et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12‑year observational study. Clin Endocrinol (Oxf) 2008; 68: 66–71.
31. Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 265–273.
32. Klibanski A. Clinical practice. Prolactinomas. N Engl J Med 2010; 362: 1219–1226.
33. Dekkers OM, Lagro J, Burman P et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta‑analysis. J Clin Endocrinol Metab 2010; 95: 43–51.
34. Stewart PM, Petersenn S. Rationale for treatment and therapeutic options in Cushing’s disease. Best Pract Res Clin Endocrinol Metab 2009; 23 (Suppl 1): S15–S22.
35. Feelders RA, de Bruin C, Pereira AM et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing‘s disease. N Engl J Med 2010; 362: 1846–1848.
36. Beck‑Peccoz P, Persani L, Mannavola D et al. Pituitary tumours: TSH‑secreting adenomas. Best Pract Res Clin Endocrinol Metab 2009; 23: 597–506.
37. Gabalec F, Čáp J. Klinicky afunkční adenomny hypofýzy – možnosti farmakologické léčby. DMEV 2009; 12: 94–98.
38. Liščák R, Vladyka V, Marek J et al. Gamma knife radiosurgery for endocrine‑inactive pituitary adenomas. Acta Neurochir (Wien) 2007; 149: 999–1006.
39. Peverelli E, Olgiati L, Locatelli M et al. The dopamine‑somatostatin chimeric compound BIM‑23A760 exerts antiproliferative and cytotoxic effects in human non‑functioning pituitary tumors by activating ERK ½ and p38 pathways. Cancer Lett 2010; 288: 170–176.
40. Neff LM, Weil M, Cole A et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 2007; 10: 81–86.
41. Syro LV, Scheithauer BW, Ortiz LD et al. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens) 2009; 8: 303–306.